

Listing of Claims

STEVEN J. SARUSSE


312-913-0001

This listing of claims will replace all prior versions and listings of claims in the application.

172 IS CANCELLED!

Claims 1-187 (cancelled)

Claim 188 (new) A compound of the formula



or a pharmaceutically acceptable salt thereof wherein

*A1*  
R<sub>1</sub> is:

- (I) C<sub>1</sub>-C<sub>6</sub> alkyl, unsubstituted or substituted with one, two or three C<sub>1</sub>-C<sub>3</sub> alkyl, -F, -Cl, -Br, -I, -OH, -NH<sub>2</sub>, -C≡N, -CF<sub>3</sub>, or -N<sub>3</sub>,
- (II) -(CH<sub>2</sub>)<sub>1-2</sub>-S-CH<sub>3</sub>,
- (III) -CH<sub>2</sub>-CH<sub>2</sub>-S-CH<sub>3</sub>,
- (IV) -CH<sub>2</sub>-(C<sub>2</sub>-C<sub>6</sub> alkenyl) unsubstituted or substituted by one -F,
- (V) -(CH<sub>2</sub>)<sub>0-3</sub>-(R<sub>1-aryl</sub>) where R<sub>1-aryl</sub> is phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, tetralinyl unsubstituted or independently substituted on the aryl ring with one or two of C<sub>1</sub>-C<sub>3</sub> alkyl, -CF<sub>3</sub>, -F, Cl, -Br, -I, C<sub>1</sub>-C<sub>3</sub> alkoxy, -O-CF<sub>3</sub>, -NH<sub>2</sub>, -OH, or -C≡N;

R<sub>2</sub> is:

- (I) -H,
- (II) C<sub>1</sub>-C<sub>6</sub> alkyl, or

(III)  $-(CH_2)_{0-4}-R_{2-1}$  where  $R_{2-1}$  is  $(C_3-C_6)$ cycloalkyl,  $R_{1-aryl}$  where  $R_{1-aryl}$  is optionally substituted with  $R_{100}$ , where  $R_{100}$  is

- A<sup>1</sup>
- (1)  $C_1-C_6$  alkyl,
  - (2)  $-F$ ,  $-Cl$ ,  $-Br$ , or  $-I$ ,
  - (3)  $-OH$ ,
  - (4)  $-NO_2$ ,
  - (5)  $-CO-OH$ ,
  - (6)  $-C\equiv N$ ,
  - (7)  $-CO-NR_{N-2}R_{N-3}$  where  $R_{N-2}$  and  $R_{N-3}$  are the same or different and are:
    - (a)  $-H$ ,
    - (b)  $-C_1-C_6$  alkyl unsubstituted or substituted with one  $-OH$  or  $-NH_2$ ,
    - (c)  $-C_1-C_6$  alkyl unsubstituted or substituted with one to three  $-F$ ,  $-Cl$ ,  $-Br$ , or  $-I$ ,
    - (d)  $-C_3-C_7$  cycloalkyl,
    - (e)  $-(C_1-C_2 \text{ alkyl})-(C_3-C_7 \text{ cycloalkyl})$ ,
    - (f)  $-(C_1-C_6 \text{ alkyl})-O-(C_1-C_3 \text{ alkyl})$ ,
    - (g)  $-C_1-C_6$  alkenyl with one or two double bonds,
    - (h)  $-C_1-C_6$  alkynyl with one or two triple bonds,
    - (i)  $-C_1-C_6$  alkyl chain with one double bond and one triple bond,
  - (8)  $-CO-(C_3-C_{12} \text{ alkyl})$ ,
  - (9)  $-CO-(C_3-C_6 \text{ cycloalkyl})$ ,
  - (11)  $-CO-R_{1-heterocycle}$  where  $R_{1-heterocycle}$  is morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, or tetrahydrothiophenyl,

where the  $R_1$ -heterocycle group is bonded by any atom of the parent  $R_1$ -heterocycle group substituted by hydrogen such that the new bond to the  $R_1$ -heteroaryl group replaces the hydrogen atom and its bond, where heterocycle is unsubstituted or substituted with one or two

=O,  $C_1$ - $C_3$  alkyl,  $-CF_3$ ,  $-F$ ,  $Cl$ ,  $-Br$ ,  $-I$ ,  $C_1$ - $C_3$  alkoxy,  $-OCF_3$ ,  $-NH_2$ ,  $-OH$ , or  $-C\equiv N$ ,

(12)  $-CO-R_{N-4}$  where  $R_{N-4}$  is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two  $C_1$ - $C_3$  alkyl,

(13)  $-CO-O-R_{N-5}$  where  $R_{N-5}$  is:

(a)  $C_1$ - $C_6$  alkyl, or

(b)  $-(CH_2)_{0-2}-(R_1\text{-aryl})$  where  $R_1\text{-aryl}$  is as defined above,

(14)  $-SO_2-NR_{N-2}R_{N-3}$  where  $R_{N-2}$  and  $R_{N-3}$  are as defined above,

(15)  $-SO-(C_1-C_8 \text{ alkyl})$ ,

(16)  $-SO_2-(C_3-C_{12} \text{ alkyl})$ ,

(17)  $-NH-CO-O-R_{N-5}$  where  $R_{N-5}$  is as defined above,

(18)  $-NH-CO-N(C_1-C_3 \text{ alkyl})_2$ ,

(19)  $-N-CS-N(C_1-C_3 \text{ alkyl})_2$ ,

(20)  $-N(C_1-C_3 \text{ alkyl})-CO-R_{N-5}$  where  $R_{N-5}$  is as defined above,

(21)  $-NR_{N-2}R_{N-3}$  where  $R_{N-2}$  and  $R_{N-3}$  can be the same or different and are as defined above,

(22)  $-R_{N-4}$  where  $R_{N-4}$  is as defined above,

(23)  $-O-CO-(C_1-C_6 \text{ alkyl})$ ,

(24)  $-O-CO-N(C_1-C_3 \text{ alkyl})_2$ ,

(25)  $-O-CS-N(C_1-C_3 \text{ alkyl})_2$ ,

- (26) -O-(C<sub>1</sub>-C<sub>6</sub> alkyl),  
 (27) -O-(C<sub>2</sub>-C<sub>5</sub> alkyl)-COOH,  
 (28) -S-(C<sub>1</sub>-C<sub>6</sub> alkyl),  
 (29) C<sub>1</sub>-C<sub>6</sub> alkyl unsubstituted or substituted with 1,  
 2, 3, 4, or 5 -F,  
 (30) -O-(C<sub>1</sub>-C<sub>6</sub> alkyl unsubstituted or substituted with  
 1, 2, 3, 4, or 5 -F, or  
 (31) -O- $\phi$ ,

R<sub>2-4</sub> is phenyl that is independently substituted with one, two,  
 three or four of R<sub>100</sub>;

R<sub>a</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sub>c</sub> is

A<sup>1</sup> R<sub>cx</sub> where R<sub>cx</sub> is morpholinyl, thiomorpholinyl,  
 thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide,  
 piperazinyl, homopiperazinyl, pyrrolidinyl,  
 pyrrolinyl, tetrahydropyranyl, piperidinyl,  
 tetrahydrofuranyl, or tetrahydrothiophenyl, each of  
 which is optionally substituted with  
 oxo, C<sub>1</sub>-C<sub>3</sub> alkyl, -CF<sub>3</sub>, -F, Cl, -Br or -I, C<sub>1</sub>-C<sub>3</sub>  
 alkoxy, -O-CF<sub>3</sub>, -NH<sub>2</sub>, -OH, or -C $\equiv$ N;

R<sub>cy</sub> where R<sub>cy</sub> is pyridinyl, pyrimidinyl, quinolinyl, indenyl,  
 indanyl, benzothiophenyl, indolyl, indolinyl,  
 pyridazinyl, pyrazinyl, isoindolyl, isoquinolyl,  
 quinazolinyl, quinoxalinyl, ~~thalazinyl~~, ~~idazolyl~~,  
 isoxazolyl, pyrazolyl, oxazolyl, thiazolyl,  
 indolizinyl, indazolyl, benzothiazolyl,  
 benzimidazolyl, benzofuranyl, furanyl, thienyl,  
 pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl,  
 tetrazolyl, 1, 4-benzodioxanyl, purinyl,  
 oxazolopyridinyl, imidazopyridinyl, isothiazolyl,  
 naphthyridinyl, cinnolinyl, carbazolyl,  $\beta$ -carbolinyl,

isochromanyl, chromanyl, furazanyl,  
tetrahydroisoquinoline, isoindolinyl,  
isobenzotetrahydrofuranlyl, isobenzotetrahydrothienyl,  
isobenzothiophenyl, benzoxazolyl, or pyridopyridinyl,  
each of which is optionally substituted with C<sub>1</sub>-C<sub>3</sub> alkyl,  
-CF<sub>3</sub>, -F, Cl, -Br, or I, C<sub>1</sub>-C<sub>3</sub> alkoxy, -O-CF<sub>3</sub>, -NH<sub>2</sub>, -OH,  
or -C≡N;  
- (C<sub>1</sub>-C<sub>10</sub>) alkyl-R<sub>CH</sub>; or  
- (C<sub>1</sub>-C<sub>10</sub>) alkyl-R<sub>CH</sub>.

188  
Claim 189 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-  
(piperidine-1-carbonyl)-hexyl]-N,N-dipropyl-isophthalamide.

188  
Claim 190 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-(2-  
morpholin-4-yl-ethylcarbamoyl)-pentyl]-5-methyl-N,N-dipropyl-  
isophthalamide.

188  
Claim 191 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-  
[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-pentyl]-5-methyl-N,N-  
dipropyl-isophthalamide.

188  
Claim 192 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-methyl-5-  
morpholin-4-yl-5-oxo-pentyl]-5-methyl-N,N-dipropyl-  
isophthalamide.

188  
Claim 193 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-4-(R)-[(furan-2-ylmethyl)-

carbamoyl]-2-(S)-hydroxy-pentyl)-5-methyl-N,N-dipropyl-isophthalamide.

194. (new) A pharmaceutical composition comprising a compound according to claim 188 in combination with a pharmaceutically acceptable carrier.

195. (new) A method ~~according~~ of treating ~~or preventing~~ Alzheimer's Disease comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 188.

---